Best in Biotech 16 Apr 2024 Seven biotech companies climbing their way up in Colorado …$4 million public offering. BioLoomics Based in Boulder, Colorado, BioLoomics is a biotech company that develops targeted antibody therapies. Late last year, it raised $8.7 million in a seed round… April 16, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 Astellas gastric cancer drug meets phase 3 primary endpoint …that includes capecitabine and oxaliplatin). Zolbetuximab is an investigational first-in-class claudin-18.2 (CLDN18.2) targeted monoclonal antibody, for the first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric… December 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2019 German Alzheimer’s Drug Backed with €43M After Biogen’s Surprise Turnaround …announced that it will apply for FDA approval for an antibody drug for Alzheimer’s called aducanumab that is designed to reduce amyloid-beta and slow the progression of the disease. Aducanumab… October 24, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 28 Feb 2018 Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine …BMS’s Opdivo, an antibody binds to the PD-1 receptor, in late 2016. They also partnered with Roche to test CV301 with Roche’s Tecentriq, an antibody which binds to the ligand… February 28, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2022 Galapagos to acquire CellPoint and AboundBio to advance cell therapies …an innovative, scalable, decentralized and automated point-of-care cell therapy supply model as well as a next-generation fully human antibody-based therapeutics platform. Galapagos said the goal is to expand the current… June 22, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2022 Financing round of $21M completed for drug to treat autoimmune diseases …entered into the worldwide agreement for the investigational anti-CD38 monoclonal antibody, CID-103, for the treatment, prevention, and diagnosis of autoimmune diseases, conditions, and disorders in humans. Strong activity CID-103 is… July 11, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 21 May 2020 What 2019 Can Teach About European Biotech Investments Going Forward …the Nasdaq Stock Exchange. The Danish company Genmab also pulled off a €450M Nasdaq IPO to fund the development of its antibody drug pipeline. In addition to these huge fundraises,… May 21, 2020 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 5 Dec 2022 The biggest private biotech investments in November 2022 …vaccine manufacturing and antibody production. November’s highlights Aside from private funding rounds, the biotech industry saw some encouraging moments in the last few weeks. One was positive phase 3 results… December 5, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 26 Jun 2024 Biotech megadeals: Exploring the surge in $100M+ deals …molecule therapies driving megadeals in the biotech industry. “The Inflation Reduction Act granted large molecule therapies (gene and protein-based therapies, immunotherapies, hormonal regulators, and antibody-drug conjugates), a much longer patent… June 26, 2024 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jan 2018 Novartis Takes Genmab’s Leukemia Drug Off the Market …a monoclonal antibody that targets CD20 proteins on the surface of leukemia cells. The antibody binds to the proteins, alerting the immune system, which can then hunt down and kill… January 22, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2016 Find Out what’s Hot in the Latin American Biotech scene …and antibody specificity testing. In these areas, it has developed its MTB Array for Tuberculosis Proteome Microarray and FastMAb for custom antibody development. CDI is also pursuing a Protein Capture… November 17, 2016 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 12 Apr 2017 Video Interview: How Morphosys Grew Into a Billion-Euro Biotech …biotech in Germany, Morphosys. Their topics ranged from Morphosys’ current pipeline and previous failures to the immuno-oncology hype and company culture. Morphosys started out with its proprietary antibody technology platform… April 12, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email